Table 1 Clinical trials evaluating CAR-NK cells
From: Development of NK cell-based cancer immunotherapies through receptor engineering
CAR Target | NK source | Target cancers | Date | Phase | Status | Number | |
|---|---|---|---|---|---|---|---|
Solid tumors | 5T4 Oncofetal Trophoblast Glycoprotein | Not disclosed | Advanced Solid Tumors | 2022 | I | Recruiting | NCT05194709 |
CD70 | CB-derived NK cells | Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma | 2023 | I/II | Recruiting | NCT05703854 | |
CLDN6 | Patient-PB-NK cells | CLDN6-positive Advanced Solid Tumors | 2022 | I/II | Recruiting | NCT05410717 | |
DLL3 | Not disclosed | Extensive Stage Small Cell Lung Cancer | 2022 | I | Recruiting | NCT05487651 | |
HER2 | NK cell line | Recurrent HER2-positive Glioblastoma | 2017 | I | Unknown | NCT03383978 | |
Mesothelin | Autologous | Refractory Epithelial Ovarian Carcinoma | 2021 | 0 | Recruiting | ChiCTR2100048100 | |
iPSC-derived NK cells | Epithelial Ovarian Cancer | 2018 | I | Unknown | NCT03692637 | ||
Muc1 | Not disclosed | MUC1-Positive Relapsed or Refractory Solid Tumor | 2016 | I/II | Unknown. | NCT02839954 | |
NKG2D ligands | Not disclosed | Platinum-Resistant Recurrent Ovarian Cancer | 2023 | Recruiting | NCT05776355 | ||
Not disclosed | Refractory Metastatic Colorectal Cancer | 2022 | I | Recruiting | NCT05213195 | ||
Not disclosed | Metastatic Solid Tumors | 2017 | I | Completed | NCT03415100 | ||
Not disclosed | Not disclosed | Ovarian epithelial carcinoma | 2023 | I | Not yet recruiting | NCT05856643 | |
Not disclosed | Advanced Hepatocellular Carcinoma | 2023 | I | Not yet recruiting | NCT05845502 | ||
Not disclosed | Advanced Triple Negative Breast Cancer | 2023 | I | Not yet recruiting | NCT05686720 | ||
PDL1 | NK cell line | Recurrent/Metastatic Gastric or Head and Neck Cancer | 2021 | II | Recruiting | NCT04847466 | |
PSMA | iPSC-derived NK cells | Metastatic Castration-Resistant Prostate Cancer | 2018 | I | Unknown | NCT03692663 | |
ROBO1 | Not disclosed | Pancreatic Cancer | 2019 | I/II | Recruiting | NCT03941457 | |
Not disclosed | Solid Tumors | 2019 | I/II | Recruiting | NCT03940820 | ||
Not disclosed | Malignant Tumor | 2019 | I/II | Recruiting | NCT03931720 | ||
TROP2 | CB-derived NK cells | Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | 2023 | I/II | Not yet recruiting | NCT05922930 | |
Hematologic malignancies | CD33 | Not disclosed | Relapsed/Refractory Acute Myeloid Leukemia | 2021 | I | Not yet ecruiting | NCT05008575 |
NK cell line | Relapsed/Refractory Acute Myeloid Leukemias | 2016 | I/II | Unknown | NCT02944162 | ||
CD33/TIM3 | CB-derived NK cells | Acute Myeloid Leukemia | 2021 | 0 | Recruiting | ChiCTR2100043081 | |
CD33/CLL1 | Not disclosed | Relapsed/Refractory Acute Myeloid Leukemia | 2021 | 0 | Recruiting | ChiCTR2100047084 | |
CD33/CCL1 | Not disclosed | Acute Myeloid Leukemia | 2020 | I | Recruiting | NCT05215015 | |
CD19 | Not disclosed | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 2023 | I | Not yet recruiting | NCT05673447 | |
iPSCs-derived NK cells | CD19-positive B-Cell Malignancies | 2023 | I | Recruiting | NCT05336409 | ||
Allogenic | B-Cell Hematologic Malignancies | 2022 | I/II | Recruiting | NCT05654038 | ||
Allogenic | Adult Relapsed/Refractory B-cell Malignancies | 2022 | I | Recruiting | NCT05645601 | ||
Not disclosed | Relapsed/Refractory Acute Lymphoblastic Leukemia | 2022 | I | Recruitment completed | NCT05563545 | ||
CB-derived NK cells | Refractory/Relapsed B-cell Non-Hodgkin Lymphoma L | 2022 | I | Recruiting | NCT05472558 | ||
Not disclosed | Relapsed/Refractory B-cell Malignancies | 2022 | I | Recruiting | NCT05410041 | ||
Allogenic | B-cell Malignancies | 2021 | I | Recruiting | NCT05020678 | ||
HLA haploidentical NK cells (PB) | Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | 2021 | I | Recruiting | NCT04887012 | ||
CB-derived NK cells | B Lymphoid Malignancies | 2021 | I | Recruiting | NCT04796675 | ||
Not disclosed | Relapsed/refractory B-cell Acute Lymphoblastic Leukemia | 2021 | I | Recruiting | NCT05379647 | ||
iPSC-derived NK cells | B-cell Lymphoma or Chronic Lymphocytic Leukemia. | 2020 | I | Recruiting | NCT04245722 | ||
Not disclosed | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | 2020 | I | Not yet ecruiting | NCT04639739 | ||
Not disclosed | Relapsed and Refractory B-Cell Lymphoma | 2019 | I | Unknown | NCT03824951 | ||
iPSC-derived NK cells | Relapsed and Refractory B-Cell Lymphoma | 2018 | I | Unknown | NCT03690310 | ||
UC and CB-derived NK cells | B Lymphoid Malignancies | 2017 | I/II | Completed [38] | NCT03056339 | ||
NK cell line | CD19 Positive Leukemia and Lymphoma | 2016 | I/II | Unknown | NCT02892695 | ||
PB NK cells (allogenic) | Relapsed and Refractory Lymphoma | 2013 | I | Completed. | NCT01974479 | ||
PB NK cells (allogenic) | Relapsed and/or Refractory Acute Lymphoid Leukemias | 2009 | I | Completed. | NCT00995137 | ||
CD19/CD22 | iPSC-derived NK cells | Relapsed and Refractory B-Cell Lymphoma | 2019 | I | Not yet recruiting. | NCT03824964 | |
CD19/CD70 | CB-derived NK cells | Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | 2023 | I/II | Recruiting | NCT05842707 | |
CB-derived NK cells | Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | 2022 | I | Recruiting | NCT05667155 | ||
CD70 | CB-derived NK cells | Relapse/Refractory Hematological Malignances | 2021 | I/II | Recruiting | NCT05092451 | |
CD7 | Allogenic | CD7 Hematologic Malignancies | 2022 | I | Not yet recruiting | NCT05377827 | |
NK cell line | CD7 Positive Relapsed or Refractory Leukemia and Lymphoma | 2016 | I/II | Unknown | NCT02742727 | ||
Not disclosed | Hematological Malignancies | 2023 | I | Recruiting | NCT05995028 | ||
CD123 | Allogenic | Refractory/Relapsed Acute Myeloid Leukemia | 2022 | I | Recruiting | NCT05574608 | |
Not disclosed | Refractory/Relapsed Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm | 2023 | I/II | Recruiting | NCT06006403 | ||
CD5 ( + IL15) | CB-derived NK cells | Relapse/Refractory Hematological Malignances | 2021 | I/II | Recruiting | NCT05110742 | |
CD56 | Not disclosed | Relapsed/Refractory NK/T-cell lymphoma/NK cell leukemia | 2023 | II | Recruiting | NCT05941156 | |
CD20 | iPSC-derived NK cells | Relapsed/Refractory Acute Myelogenous Leukemia and B-Cell Lymphoma | 2019 | I | Active | NCT04023071 | |
CD22 | iPSC-derived NK cells | Relapsed and Refractory B-Cell Lymphoma | 2018 | I | Unknown | NCT03692767 | |
CD33/CLL1 | Not disclosed | Acute Myeloid Leukemia | 2023 | I | Not yet recruiting | NCT05987696 | |
CCL1 | iPSC-derived NK cells | Acute Myeloid Leukemia | 2023 | I | Recruiting | NCT06027853 | |
CD38/SLAMF7 | iPSC-derived NK cells | Acute myeloid leukemia and multiple myeloma | 2020 | I | Active | NCT04614636 | |
BCMA | Allogenic | Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | 2023 | I | Recruiting | NCT06045091 | |
Allogenic | Relapsed/Refractory Multiple Myeloma | 2022 | I | Recruiting | NCT05652530 | ||
iPSCs-derived NK cells | Multiple myeloma | 2021 | I | Recruiting | NCT05182073 | ||
UC and CB-derived NK cells | Relapse/Refractory Multiple Myeloma | 2021 | I | Recruiting | NCT05008536 | ||
NK cell line | Relapse/Refractory Multiple Myeloma | 2019 | I/II | Recruiting | NCT03940833 | ||
iPSC-derived NK cells | Relapsed/Refractory B-Cell Lymphoma | 2018 | I | Unknown | NCT03559764 | ||
NKG2D ligands | Not disclosed | Relapsed/Refractory Acute Myeloid Leukemia | 2023 | Recruiting | NCT05734898 | ||
CB-derived NK cells | Relapsed/Refractory Acute Myeloid Leukemia | 2022 | Recruitment completed | NCT05247957 | |||
PB NK cells | Myelodysplastic Syndromes and Acute Myeloid Leukemia | 2020 | I | Recruiting | NCT04623944 | ||
Not disclosed | Not disclosed | B-Cell Malignancies | 2021 | I/II | Recruiting | NCT04747093 | |
Not disclosed | Relapsed/Refractory Hematological Malignancies | 2021 | I | Recruiting | NCT04796688 | ||
Other | NKG2D ligands – SARS-CoV-2 envelope glycoprotein | CB-derived NK cells | COVID-19 | 2020 | I/II | Recruiting | NCT04324996 |
